Jacobs Levy Equity Management, Inc Cytom X Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 1,524,076 shares of CTMX stock, worth $1.52 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,524,076
Previous 1,507,717
1.09%
Holding current value
$1.52 Million
Previous $1.84 Million
2.23%
% of portfolio
0.01%
Previous 0.01%
Shares
28 transactions
Others Institutions Holding CTMX
# of Institutions
68Shares Held
50.4MCall Options Held
112KPut Options Held
8.3K-
Tang Capital Management LLC San Diego, CA7.81MShares$7.81 Million0.79% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$5.23 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.16MShares$5.16 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X04.81MShares$4.81 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.1MShares$3.1 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $66M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...